5Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature,2001,414:813-820.
6Ziegler D, Hanefold M, Ruhnan Kj,et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid: a 3-week multicentre randomized controlled trial(ALADIN study). Diabetologia, 1995,38 : 1425-1433.
7Da Ros R, Assaloni R,Ceriello A. Molecular targets of diabetic vascular complications and potential new drugs. Curr Drug Targets,2005,6:503-509.
8Yorek MA, Coppey LJ, Gellett .IS, et al. Effect of fidarestat and alpha-lipoic acid on diabetes-induced epineurial arteriole vascular dysfunction.Exp Diabesity Res ,2004,5 : 123-135.
7Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic periph- eral neuropathy: consensus recommendations on diagnosis, assess- ment and management [ J ]. Diabetes/metabolism research and re- views, 2011, 27(7) : 629 -638.
8Johnston SS, Udall M, Cappelleri JC, et al. Cost comparison of drug - drug and drug - condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus du- loxetine [ J ]. Am J Health Syst Pharm, 2013,70 ( 24 ) : 2207 -2217.
9Sicras A, Ptejas J, NavalTo R, et al. Adding pregabalin or gabapen- tin for the management of community - treated patients with painful diabetic peripheral neuropathy : a comparative cost analysis [ J ]. Clin Drug Investig,2013,33( 11 ) :825 -835.
10Onofrj M, Ciccocioppo F, Varanese S, et al. Acetyl - L - camitine : from a biological curiosity to a drug for the peripheral nervous system and beyond[ J]. Expert Rev Neurother,2013,13(8) :925 -936.
